AU2018300123B2 - New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2) - Google Patents
New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2) Download PDFInfo
- Publication number
- AU2018300123B2 AU2018300123B2 AU2018300123A AU2018300123A AU2018300123B2 AU 2018300123 B2 AU2018300123 B2 AU 2018300123B2 AU 2018300123 A AU2018300123 A AU 2018300123A AU 2018300123 A AU2018300123 A AU 2018300123A AU 2018300123 B2 AU2018300123 B2 AU 2018300123B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- disease
- optionally substituted
- ino
- pyrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382447 | 2017-07-10 | ||
| EP17382447.5 | 2017-07-10 | ||
| PCT/ES2018/070491 WO2019012172A1 (es) | 2017-07-10 | 2018-07-09 | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018300123A1 AU2018300123A1 (en) | 2020-02-13 |
| AU2018300123B2 true AU2018300123B2 (en) | 2022-03-17 |
Family
ID=59315557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018300123A Active AU2018300123B2 (en) | 2017-07-10 | 2018-07-09 | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2) |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11241428B2 (enExample) |
| EP (1) | EP3653620B9 (enExample) |
| JP (1) | JP7026787B2 (enExample) |
| KR (1) | KR102574135B1 (enExample) |
| CN (1) | CN111051300B (enExample) |
| AU (1) | AU2018300123B2 (enExample) |
| CA (1) | CA3069273A1 (enExample) |
| CY (1) | CY1125343T1 (enExample) |
| DK (1) | DK3653620T3 (enExample) |
| EA (1) | EA039144B1 (enExample) |
| ES (1) | ES2911040T3 (enExample) |
| HR (1) | HRP20220472T1 (enExample) |
| HU (1) | HUE058353T2 (enExample) |
| LT (1) | LT3653620T (enExample) |
| MX (1) | MX393982B (enExample) |
| PL (1) | PL3653620T3 (enExample) |
| PT (1) | PT3653620T (enExample) |
| RS (1) | RS63156B1 (enExample) |
| SI (1) | SI3653620T1 (enExample) |
| SM (1) | SMT202200165T1 (enExample) |
| WO (1) | WO2019012172A1 (enExample) |
| ZA (1) | ZA202000727B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4074700A4 (en) * | 2019-12-10 | 2024-02-07 | Shionogi & Co., Ltd | HISTONE DEACETYLASE INHIBITOR COMPRISING AROMATIC HETEROCYCLIC GROUP CONTAINING NITROGEN |
| CN114380751B (zh) * | 2020-03-30 | 2025-03-07 | 上海辉启生物医药科技有限公司 | 二氢化茚胺类衍生物、其制备方法和用途 |
| WO2023102162A1 (en) | 2021-12-03 | 2023-06-08 | Tango Therapeutics, Inc. | Tgonovel hdac inhibitors and therapeutic use thereof |
| CN114524799B (zh) * | 2022-03-11 | 2023-05-26 | 沈阳药科大学 | 一种hdac抑制剂及其制备方法和用途 |
| EP4306106A1 (en) * | 2022-07-14 | 2024-01-17 | Universidade de Aveiro | Nitro-containing compounds, compositions and uses thereof |
| CN115463215A (zh) * | 2022-07-26 | 2022-12-13 | 苏州大学 | Hdac9及其抑制剂的新用途 |
| JP2025525945A (ja) | 2022-08-05 | 2025-08-07 | タンゴ セラピューティクス， インコーポレイテッド | Ｓｔｋ１１活性または発現が改変されているがんを処置するためのｈｄａｃ阻害剤 |
| CN115304513A (zh) * | 2022-08-25 | 2022-11-08 | 湖北科技学院 | 具有抗炎活性的查尔酮类衍生物及其合成方法和应用 |
| CN115368277B (zh) * | 2022-09-15 | 2024-03-29 | 华侨大学 | 一种含异羟肟酸结构的联苯类化合物及其应用 |
| CN116199636A (zh) * | 2023-02-21 | 2023-06-02 | 杭州医学院 | 靶向肿瘤免疫激酶的2,4-二取代嘧啶衍生物、制备方法及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057779A2 (en) * | 2014-10-08 | 2016-04-14 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006312084A1 (en) | 2005-11-03 | 2007-05-18 | Merck Sharp & Dohme Corp. | Substituted nicotinamide compounds |
| CA2649861A1 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| WO2009005638A2 (en) | 2007-06-27 | 2009-01-08 | Merck & Co., Inc. | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
| EP2440519A1 (en) | 2009-06-08 | 2012-04-18 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| CA2990660A1 (en) * | 2015-07-02 | 2017-01-05 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US9603950B1 (en) | 2015-10-25 | 2017-03-28 | Institute Of Nuclear Energy Research | Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof |
-
2018
- 2018-07-09 ES ES18789777T patent/ES2911040T3/es active Active
- 2018-07-09 SI SI201830644T patent/SI3653620T1/sl unknown
- 2018-07-09 SM SM20220165T patent/SMT202200165T1/it unknown
- 2018-07-09 US US16/629,457 patent/US11241428B2/en active Active
- 2018-07-09 WO PCT/ES2018/070491 patent/WO2019012172A1/es not_active Ceased
- 2018-07-09 MX MX2020000349A patent/MX393982B/es unknown
- 2018-07-09 LT LTEPPCT/ES2018/070491T patent/LT3653620T/lt unknown
- 2018-07-09 AU AU2018300123A patent/AU2018300123B2/en active Active
- 2018-07-09 CA CA3069273A patent/CA3069273A1/en active Pending
- 2018-07-09 DK DK18789777.2T patent/DK3653620T3/da active
- 2018-07-09 JP JP2020523052A patent/JP7026787B2/ja active Active
- 2018-07-09 PT PT187897772T patent/PT3653620T/pt unknown
- 2018-07-09 EP EP18789777.2A patent/EP3653620B9/en active Active
- 2018-07-09 HU HUE18789777A patent/HUE058353T2/hu unknown
- 2018-07-09 CN CN201880056722.5A patent/CN111051300B/zh active Active
- 2018-07-09 KR KR1020207003894A patent/KR102574135B1/ko active Active
- 2018-07-09 RS RS20220320A patent/RS63156B1/sr unknown
- 2018-07-09 HR HRP20220472TT patent/HRP20220472T1/hr unknown
- 2018-07-09 PL PL18789777T patent/PL3653620T3/pl unknown
- 2018-07-09 EA EA202090259A patent/EA039144B1/ru unknown
-
2020
- 2020-02-04 ZA ZA2020/00727A patent/ZA202000727B/en unknown
-
2022
- 2022-04-15 CY CY20221100286T patent/CY1125343T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057779A2 (en) * | 2014-10-08 | 2016-04-14 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7026787B2 (ja) | 2022-02-28 |
| CN111051300A (zh) | 2020-04-21 |
| US20200138808A1 (en) | 2020-05-07 |
| MX2020000349A (es) | 2020-08-17 |
| EP3653620A1 (en) | 2020-05-20 |
| US11241428B2 (en) | 2022-02-08 |
| KR102574135B1 (ko) | 2023-09-01 |
| EP3653620B9 (en) | 2022-03-23 |
| JP2020527173A (ja) | 2020-09-03 |
| LT3653620T (lt) | 2022-05-10 |
| AU2018300123A1 (en) | 2020-02-13 |
| EA202090259A1 (ru) | 2020-05-25 |
| ES2911040T3 (es) | 2022-05-17 |
| MX393982B (es) | 2025-03-24 |
| KR20200038473A (ko) | 2020-04-13 |
| CY1125343T1 (el) | 2024-12-13 |
| DK3653620T3 (da) | 2022-03-28 |
| PT3653620T (pt) | 2022-04-22 |
| WO2019012172A1 (es) | 2019-01-17 |
| EA039144B1 (ru) | 2021-12-09 |
| SMT202200165T1 (it) | 2022-05-12 |
| SI3653620T1 (sl) | 2022-05-31 |
| EP3653620B1 (en) | 2022-02-02 |
| ZA202000727B (en) | 2022-07-27 |
| RS63156B1 (sr) | 2022-05-31 |
| CA3069273A1 (en) | 2019-01-17 |
| HRP20220472T1 (hr) | 2022-05-27 |
| HUE058353T2 (hu) | 2022-07-28 |
| CN111051300B (zh) | 2022-12-23 |
| BR112020000564A2 (pt) | 2020-07-21 |
| PL3653620T3 (pl) | 2022-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018300123B2 (en) | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2) | |
| JP7653362B2 (ja) | 二環式化合物 | |
| CA2890981C (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses | |
| AU2005259894C1 (en) | Pyrrolotriazine kinase inhibitors | |
| CA2823824C (en) | Derivatives of azaindazoles and diazaindazoles and their use as medicaments | |
| ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
| KR20100016076A (ko) | 신규 피롤리논 유도체 및 그것을 함유하는 의약 조성물 | |
| WO2016022460A1 (en) | Potent dual brd4-kinase inhibitors as cancer therapeutics | |
| JP2006518341A (ja) | ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としてのヒドロキサム酸誘導体 | |
| AU2017226005A1 (en) | Inhibitors of WDR5 protein-protein binding | |
| KR20190080951A (ko) | 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도 | |
| CN105722840B (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
| CN108290897A (zh) | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 | |
| US20190092761A1 (en) | Methods and Compositions for Inhibition of Bromodomain and Extratermial Proteins | |
| WO2014029726A1 (en) | Novel phenyl-pyridine/pyrazine amides for the treatment of cancer | |
| CN107074856A (zh) | CaMKII抑制剂及其用途 | |
| WO2011131135A1 (zh) | 芳杂（烷基）氨基二硫代甲酸酯类化合物、其制备方法和应用 | |
| JP2019509272A (ja) | 脊髄性筋萎縮症の治療のための併用療法 | |
| WO2018140648A1 (en) | Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer | |
| WO2023146513A1 (en) | Compounds and methods of use thereof | |
| CA3178647A1 (en) | Substituted tricyclic amides, analogues thereof, and methods using same | |
| CN106366078A (zh) | 吲唑-噁二唑类衍生物、含其的药物组合物及其在抗肿瘤中的应用 | |
| BR112020000564B1 (pt) | Composto de heteroarilamida como inibidor seletivo das histonas desacetilases 1 e/ou 2 (hdac1-2), composição farmacêutica, uso e combinação do mesmo | |
| KR20230118883A (ko) | Enpp1 억제제로서의 이미다졸 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |